CGIM
VIR icon

Cannon Global Investment Management’s Vir Biotechnology VIR Stock Holding History

Cannon Global Investment Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-20,276
Closed -$521K – 65
2022
Q1 		$521K Buy
+20,276
New +$601K 0.38% 59

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Cannon Global Investment Management's VIR Position: Q2 2022 in Review

Cannon Global Investment Management sold out of Vir Biotechnology (VIR) in Q2 2022, closing a stake of 20,276 shares — an estimated $521K sold.

Cannon Global Investment Management first reported a position in VIR in Q1 2022 and held it in 1 quarter. The position peaked at $521K in Q1 2022. 211 funds tracked by Wall St. Rank hold VIR as of Q2 2022.

  • Cannon Global Investment Management reported no remaining Vir Biotechnology position as of Q2 2022 after selling out during the quarter.
  • Cannon Global Investment Management sold 20,276 Vir Biotechnology shares in Q2 2022, an estimated $521K.
  • Cannon Global Investment Management first reported a position in Vir Biotechnology in Q1 2022 and held it in 1 quarter.
  • Cannon Global Investment Management's Vir Biotechnology position peaked at $521K in Q1 2022.
  • 211 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2022.

Based on Cannon Global Investment Management's 13F filing for Q2 2022, filed 4 Aug 2022.